Cyndi Chua

Commissioning Editor, Frontiers in Bioscience-Landmark (ISSN: 2768-6701, SCIE&PubMed Indexed, IF: 4.1), IMR Press
Email: [email protected]

[Cyndi Chua @ChuaCyndi2020]

📢 Official Announcement:

I am Cyndi Chua, the official editor of @Landmark_IMR. If you're interested in submitting your work or have questions about our submission process, feel free to DM me via Twitter or ([email protected]). Looking forward to your contributions!

[Frontiers in Bioscience-Landmark @Landmark_IMR]

🚀Big news! Frontiers in Bioscience-Landmark (FBL) hits a new high in #JCR2025!

📈 Impact Factor soared from 3.1 to 4.1!
🏆 Promoted to Q2 in #Biochemistry & #MolecularBiology/#CellBiology!

�� Thanks to our Editor-in-Chief, Editorial Board, authors, reviewers & readers!

#ImpactFactor #FBL #AcademicTwitter #Clarivate #AcademicPublishing #ScientificResearch #IMRPress

[Frontiers in Bioscience-Landmark @Landmark_IMR]

🎤 Special Interview with Frontiers in Bioscience-Landmark Author Dr. Gabriel Žoldák: ���� Exploring Microbial Load and New Directions in Gut Microbiome Research

👉Interview details: https://t.co/GoxWmnaQZN

📖 Recently, Dr. Gabriel Žoldák and his team published a commentary article in FBL entitled “Gut Microbial Load as a Hidden Driver of Microbiome Diversity and Function” (Volume 30, Issue 8, 2025).

🔬 In this article, the authors provide an in-depth analysis of the study by Nishijima et al. published in Cell, highlighting the critical importance of absolute microbial abundance in microbiome research and its potential implications for clinical translation.

🔎 To further explore the story behind this research, its innovative significance, and future directions, we interviewed Dr. Gabriel Žoldák's team.

📄 Article: https://t.co/Bnq7NshtPt

#Microbiome #GutHealth #MicrobialLoad #TranslationalResearch #LifeSciences #ResearchInsights #Interview

[Frontiers in Bioscience-Landmark @Landmark_IMR]

We warmly invite you to submit to the Special Issue:
Pathogenesis and Molecular Drivers of Osteoarthritis
Guest-Edited by Dr. Ye Liu and Dr. Vladimir M. Molchanov @V_Molchanov1 from Van Andel Research Institute @VAInstitute
📖 For more details, please see: https://t.co/GQyUXIWAeI

👉 This Special Issue focuses on osteoarthritis as a whole-joint disease and highlights recent advances in molecular, metabolic, and epigenetic mechanisms involved in OA initiation and progression, with emphasis on early tissue-specific changes and predictive biomarkers. Contributions exploring joint tissue interactions and multi-omics approaches are welcome.

This Special Issue aims to highlight recent advances in understanding:
✨ The molecular, metabolic, and epigenetic mechanisms underlying OA initiation and progression
✨ Early tissue-specific changes
✨ Predictive biomarkers
✨ Multi-omics approaches, including transcriptomics, epigenomics, metabolomics, proteomics,
✨ Tissue heterogeneity, cell–cell communication, and metabolic reprogramming within the joint microenvironment

🧠 Why submit to this Special Issue of FBL?
✔️ Open Access
✔️ Rapid review process
✔️ Impact Factor: 3.1
✔️ Indexed in major databases

📖 Manuscript type: Original Research; Review;
📆 Submission deadline: 31 December 2026
✍️ Submit your work to https://t.co/yoG3BUFzCT

#Osteoarthritis #OAResearch #JointBiology #MultiOmics #Epigenetics #MetabolicMechanisms #CallForPapers #OpenAccess #FBL

[Cyndi Chua @ChuaCyndi2020]

✍️Welcome submissions! Selected papers will receive the FBL 30th Anniversary Outstanding Paper Certificate, and authors will be eligible for a waived submission fee for their next submission.

[Frontiers in Bioscience-Landmark @Landmark_IMR]

📢 We warmly invite you to submit to the Special Issue:
Thirty Years at the Frontiers of Biological Knowledge: A Publishing Milestone for Frontiers in Bioscience -Landmark
Guest-Edited from University of Tübingen and Health Sciences North Research Institute by Prof. Graham Pawelec @grahampawelec

📖 For more details, please see: https://t.co/S8TNFXv1o7

🎉The year 2026 marks a major milestone for our journal, Frontiers in Bioscience-Landmark, an international peer-reviewed open-access journal of biological science, which has now been published continuously for 30 years. 🌟Thanks to the contributions of authors and generous input from peer reviewers, Frontiers in Bioscience-Landmark has published more than 5,500 papers.

💡 To celebrate this milestone, we are launching a special issue that will focus on showcasing important research advances and emerging directions in the fields of molecular and cell biology.

��� Why submit to this Special Issue of FBL?
✔️ Open Access
✔️ Rapid review process
✔️ Impact Factor: 3.1
✔️ Indexed in major databases

📆 Submission deadline: 31 December 2026
✍️ Submit your work to https://t.co/yoG3BUFzCT
📑 Click here for author guidelines: https://t.co/EBITEzbjBy

#FBL #CallForPapers #OpenAccess #ScientificPublishing #MolecularBiology #CellBiology #LifeSciences #AcademicResearch

[Frontiers in Bioscience-Landmark @Landmark_IMR]

✨ SB431542, a Selective Inhibitor of the TGF-β Type I Receptor, Enhances Doxorubicin Antitumor Activity via p63 Activation in Mutant p53 Breast Cancer Cells—Video interpretation by Bi-He Cai

🔗 Find more details: https://t.co/JEpQcIGYs1

👨‍🔬 Yu-Ling Kou, Yu-Jie Liu, and colleagues have published their article in Volume 30, Issue 12 of Frontiers in Bioscience–Landmark (FBL) (https://t.co/GDW5iV08dA).

🏥 We are honored to invite one of the corresponding authors, Dr. Bi-He Cai, to provide his expert interpretation of the article. Dr. Bi-He Cai is an Associate Professor in the School of Medicine at I-Shou University, Kaohsiung, Taiwan. 🔬 He leads the p53 Family Laboratory in Taiwan, where his research focuses on the roles of p53 family proteins in cancer progression and therapeutic resistance, aiming to identify novel targets for improved cancer therapy.

💉 In this study, we focused on breast cancer cells carrying TP53 mutations, which are more difficult to treat because mutated TP53 reduces the effectiveness of chemotherapy drugs such as doxorubicin. We asked whether blocking the TGF-β signal pathway could improve the chemotherapy response in these resistant cancer cells, using SB431542, a selective inhibitor of the TGF-β type I receptor.

🎬 Watch the video for a concise overview of this research.

#BreastCancer #TP53 #CancerResearch #Chemotherapy #TGFbeta #p53Family #TargetedTherapy #FrontiersInBioscience #VideoSummary

[Dr. Tanaka @emtanaka]

🚀Folate-tagged #Nanocarriers + #Ultrasound = dual chemo-sonodynamic punch!💥💊Safe, precise & deadly—to #Tumors, not you!😎 @IJMS_MDPI @MDPIOpenAccess #Innovation
https://t.co/CSq9rFCS7m

[Cyndi Chua @ChuaCyndi2020]

The latest work from University of Florida by Dr. Prodip Bose and his team is now featured in FBL @Landmark_IMR !

Glutamate Excitotoxicity: A Key Secondary Injury Mechanism of Traumatic Brain Injury and Spinal Cord Injury

Read this article 👉: https://t.co/sudefZlwBw

[Frontiers in Bioscience-Landmark @Landmark_IMR]

We warmly invite you to submit to the Special Issue:
Roles of Inflammasomes and Their Molecular Mechanisms
From the Kyonggi University , Guest Edited by Dr. Young-Su Yi @Youngsuyi75
📖 For more details, please see: https://t.co/inaBzTkuny

👉This Special Issue focuses on the regulatory roles and molecular mechanisms of canonical and noncanonical inflammasomes in inflammatory responses and inflammation-related diseases. It aims to deepen understanding of how inflammasome dysregulation drives disease and to promote the development of novel anti-inflammatory therapies.

Potential topics include, but are not limited to:
✨ Roles of canonical and noncanonical inflammasomes in inflammatory responses and diseases and the underlying molecular mechanisms
✨ Identification and validation of novel molecules interacting with inflammasomes
✨ Evaluation of anti-inflammatory effects through inflammasome targeting
✨ Development of potential inflammasome-targeted therapeutics

🧠 Why submit to this Special Issue of FBL?
✔️ Open Access
✔️ Rapid review process
✔️ Impact Factor: 3.1
✔️ Indexed in major databases

📕 Manuscript Type: Original Research, Comprehensive Reviews
📆 Submission deadline: 31 October 2026
✍️ Submit your work to https://t.co/yoG3BUF1Nl

#Inflammasomes #Inflammation #MolecularMechanisms #AntiInflammatoryTherapies #FBLCFP

[Frontiers in Bioscience-Landmark @Landmark_IMR]

The latest work from Charles University and General University Hospital by Prof. George B. Stefano is now featured in FBL!

Welcome to read this article 👉:
https://t.co/QeKaIWVrxy

Article Highlights
🧬 Could Darwin’s theory of evolution extend beyond living organisms — to molecules themselves?
This perspective explores how pathogen–host interactions, mitochondrial origins, and molecular self-assembly might all reflect evolutionary principles of adaptation and survival.

✒️ Author: George B. Stefano
🏪 Affiliation: Charles University and General University Hospital @CharlesUniPRG

📖 Don’t miss this citable reference for your future research!
Citation format:
George B. Stefano. Adaptability Beyond Darwin: Microbial Evolution, Mitochondria, and the Thermodynamic Frontiers of Survival. Front. Biosci. (Landmark Ed) 2025, 30(10), 45962.

Welcome to submit your work via our submission link👉: https://t.co/wHF8lp28MT
FBL is dedicated to the publication of original articles, reviews, methods and commentaries in all areas of cellular and molecular biology.
📖 Click here for author guidelines: https://t.co/Zv5c3V8FDT

#Evolution #Microbiology #HostPathogen #Mitochondria #DarwinianTheory #FBLPaper

[Dr. Tanaka @emtanaka]

😱🧠90% of #Serotonin precursors diverted—delete just one enzyme, get despair! Knocking out aadat/kat2 in mice unleashes #Depression-like behavior!⚡🔥 @istry_media @ImrPress @Landmark_IMR @ChuaCyndi2020 #PTSD #Neuroscience
Dive in & share!
https://t.co/xi5waxmIes

[Frontiers in Bioscience-Landmark @Landmark_IMR]

📢 The latest contribution from Dr. Wei-Sheng Lin and his team at National Yang Ming Chiao Tung University @NYCU_official is now featured in FBL!

Welcome to read this article 👉: https://t.co/h7ArLv6Tg8

Article Highlights
🧠 What can astrocyte-derived biomarkers reveal about epilepsy?
Emerging evidence highlights the roles of GFAP and S100B in tracking seizure activity, distinguishing epileptic from psychogenic events, and offering insights into prognosis and therapy.

✒️ Author: Ting-Rong Hsu, Pei-Hao Chen, Wei-Sheng Lin
🏪 Affiliation: Taipei Veterans General Hospital; National Yang Ming Chiao Tung University

Citation format:
Ting-Rong Hsu, Pei-Hao Chen, Wei-Sheng Lin. Astrocytic Biomarkers in Epilepsy: A Critical Review on Clinical Utility and Mechanistic Implications. Front. Biosci. (Landmark Ed) 2025, 30(9), 39022. https://t.co/sTVRiVHHKt

📖 Don’t miss this citable reference for your future research!

👉Welcome to submit your work: https://t.co/wHF8lp2GCr
#EpilepsyResearch #Neurobiology #Astrocytes #Biomarkers #Neurology #FBLPaper

[Cyndi Chua @ChuaCyndi2020]

🧬 New Review in #FBL!

Transcriptional Dysregulation of Autophagy in Aging and Potential Interventions: Insights Into TFEB and FOXOs

By @CellRepairLab @kumsta et al.
🔗 https://t.co/UFHUNyM77D

#Autophagy #Aging #MolecularBiology

[Frontiers in Bioscience-Landmark @Landmark_IMR]

📢 The latest contribution from Dr. Galina Smirnova and their team at Institute of Ecology and Genetics of Microorganisms now featured in FBL!

To read the full text, please click: 👉 https://t.co/rfmyjcZnIu

Research Highlights
How does cysteine and H₂S production shape bacterial responses to antibiotics and oxidative stress?
Why does Mycobacterium smegmatis react so differently compared to E. coli? Stay tuned for the findings!

✍️ Authors: Galina Smirnova, Aleksey Tyulenev, Tatyana Kalashnikova, Lyubov Sutormina, Vadim Ushakov, Oleg Oktyabrsky
🏪 Institution: Institute of Microbial Ecology and Genetics

Citation Format: Galina Smirnova, Aleksey Tyulenev, Tatyana Kalashnikova, Lyubov Sutormina, Vadim Ushakov, Oleg Oktyabrsky. Antibiotics alter low molecular weight thiol levels in the Mycobacterium avium complex via cysteine modification. Frontiers in Bioscience (Landmark Edition) 2025, 30(9), https://t.co/JzDEOnLIu2

📖 Don't miss this citable research resource!
👉 Submission portal: https://t.co/wHF8lp2GCr

#AntibioticResistance #BacterialMetabolism #ThioCompounds #Cysteine #FBLPaper

[Frontiers in Bioscience-Landmark @Landmark_IMR]

📢 The latest contribution from Dr. Bikesh K. Nirala and his team at Emory University is now featured in FBL!

Welcome to read this article 👉: https://t.co/AOHxjPBD2w

Article Highlights
🧬 How does the MYC oncogene family reshape the tumor immune microenvironment?
🔍 This review explores MYC’s role in immune evasion—upregulating PD-L1 & CD47, suppressing MHC, and recruiting Tregs & MDSCs—while highlighting emerging strategies to inhibit MYC and boost immunotherapy.
👉 Could MYC be the key to next-gen cancer treatments?

✒️ Author: Bikesh K. Nirala, Jason T. Yustein @JYustein
🏪 Affiliation: Emory University @EmoryUniversity

Citation format: Bikesh K. Nirala, Jason T. Yustein. The Role of MYC in Tumor Immune Microenvironment Regulation: Insights and Future Directions. Front. Biosci. (Landmark Ed) 2025, 30(9), 37304. https://t.co/SLMxuFmCLH

📖 Don’t miss this citable reference for your future research!

👉Welcome to submit your work: https://t.co/wHF8lp2GCr

#CancerResearch #Oncogenes #TumorImmunology #MYC #Immunotherapy #FBLPaper

[Cyndi Chua @ChuaCyndi2020]

🧬 New in #FBS @Scholar_IMR !
Exploratory Study on Genetic Variants Related to Hydatidosis Susceptibility and Albendazole Pharmacogenetics in the Cusco Region, Peru
By @sjsantivanez et al.

🔗 https://t.co/uYg50AXNrf

#Genetics #Pharmacogenetics #InfectiousDiseases

[Cyndi Chua @ChuaCyndi2020]

✨New Research in #FBS!

🌈Optimal Algorithm for Gut Microbiota Differentiation: A Pilot Study of Adolescents with Different Body Weights
🔗 https://t.co/wkdmkyeDWm
#Microbiome #GutHealth #AdolescentHealth

[Cyndi Chua @ChuaCyndi2020]

🧬 New in #FBL!

The Role of MYC in Tumor Immune Microenvironment Regulation: Insights and Future Directions
Exploring how MYC shapes immune responses & cancer therapy prospects.
🔗 https://t.co/CmjByb4qGd
#CancerResearch #TumorMicroenvironment #MYC

[Frontiers in Bioscience-Landmark @Landmark_IMR]

We warmly invite you to submit to the Special Issue:
Molecular Mechanisms in Oral Cancers
Guest-Edited by Prof. Chan-Yen Kuo from Tzu Chi University

📖 For more details, please see: https://t.co/UPHLsproDS

👉 Oral cancers, particularly oral squamous cell carcinoma, represent a major global health challenge with persistently high morbidity and mortality rates despite advances in surgery, radiotherapy, chemotherapy, and immunotherapy. What drives the initiation, progression, and therapeutic resistance of oral cancers?

We invite submissions on the molecular basis of oral squamous cell carcinoma, with a focus on:
✨ Cancer genomics
✨ Proteomics
✨ Metabolomics
✨ Cell signaling
✨ Tumor–host interactions
✨ Immune regulation
✨ Therapeutic innovations

🧠 Why submit to this Special Issue of FBL?
✔️ Open Access
✔️ Rapid review process
✔️ Impact Factor: 3.1
✔️ Indexed in major databases

📆 Submission deadline: 15 October 2026
✍️ Submit your work to https://t.co/yoG3BUFzCT

#OralCancers #OralSquamousCellCarcinoma #FBLCFP

[IMR Press @ImrPress]

✨Behrooz Astaneh brings us a new lesson: How to Write the Method Section

📎 Watch here:
https://t.co/ST9QSxE0lm
https://t.co/EcXXo9POta

🎥 More exciting content is on the way—stay tuned!

💬 Share your feedback: https://t.co/yszE11EKeb

#IMRPress #MethodSection

[Journal of Molecular and Clinical Medicine @JMCMIMR]

🔔 Editorial Update | We are delighted to welcome Dr. Jyoti Srivastava as the new Editorial Board Member!

💊She is a leading expert in Targeted Cancer Therapy, specializing in innovative treatment approaches.
🔗 Website:https://t.co/X3ti7c3qbz

#EditorialBoard #JMCM